Recent studies have converged on the intersection of GLP|glucose-dependent insulinotropic polypeptide|glucagon receptor activator therapies and dopamine communication. While GIP agonists are widely employed for managing type 2 T2DM, their unexpected consequences on reinforcement circuits, specifically influenced by DA pathways, are attracting consi